When the potential of OBP-702 to modulate the antitumor immune response including DCs was evaluated using the same PAN02 bilateral subcutaneous tumor model (Fig. 5A), intratumoral injection of Ad-p53 and OBP-702 significantly increased the recruitment of whole DCs (CD11b+/CD11c+/MHC-II+) and matured DCs (CD86+/CD11b+/CD11c+/MHC-II+) into draining lymph nodes, compared with OBP-301 (Fig. 5B). The gene discussed is CD86; the disease is neoplasm.